

Additional file 1:
Supplementary figures S1-S21
Trial level estimates of observed/expected
SAEs

Figure S1: Observed/expected SAEs in asthma trials




Figure S2: Observed/expected SAEs in atrial fibrillation trials




Figure S3: Observed/expected SAEs in axial spondyloarthritis trials




Figure S4: Observed/expected SAEs in benign prostatic hyperplasia trials




Figure S5: Observed/expected SAEs in dementia trials




Figure S7: Observed/expected SAEs in epilepsy trials




Figure S8: Observed/expected SAEs in hypertension trials




Figure S9: Observed/expected SAEs in pulmonary hypertension trials




Figure S10: Observed/expected SAEs in inflammatory bowel disease trials




Figure S11: Observed/expected SAEs in myocardial infarction trials




Figure S12: Observed/expected SAEs in osteoarthritis trials




Figure S13: Observed/expected SAEs in osteoporosis trials




Figure S14: Observed/expected SAEs in Parkinson's disease trials




Figure S15: Observed/expected SAEs in psoriasis trials




Figure S16: Observed/expected SAEs in psoriatic arthritis trials




Figure S17: Observed/expected SAEs in chronic obstructive pulmonary disease trials




Figure S18: Observed/expected SAEs in pulmonary fibrosis trials




Figure S19: Observed/expected SAEs in rheumatoid arthritis trials




Figure S20: Observed/expected SAEs in systemic lupus erythematosus trials




Figure S21: Observed/expected SAEs in thromboembolism trials

